Skip to main content

Our Story

Targeted biologic therapy to increase the efflux of LDL cholesterol from plaques directly by increasing Apo-A1, high-quality functional HDL, reduce plaque burden and address the associated CAD and PAD

Regio Biosciences Today

Addressing Atherosclerosis in Multiple Arterial Beds to Providing New Hope for Patients with Cardiovascular Disease CAD, PAD

Heart Icon
PIONEERING

The development of novel therapies to reduce plaque in the peripheral arteries and heart for the treatment of atherosclerosis

Spin Out Icon
SPIN-OUT FROM BIG PHARMA

Lead asset, REG-101, is a Phase 2 antibody exclusively licensed from big pharma with established human proof of mechanism and de-risked clinical profile

Leadership Icon
LEADERSHIP TEAM

Has significant cardiovascular disease drug and biologics development experience and direct involvement with the program while working in big pharma

Our Team

Experienced Team with Disease Expertise.

Leadership Team

Executive Team and Founder’s Approved Drugs: Onglyza, Kombiglyze, Qtern, Imfinzi, Moxetumomab, Fasenra, Sliq, Maxalt, Singulair, Crixivan, Vioxx, Emend, Daytrana and Multiple influenza vaccines and diagnostics.

Team members directed the development of REG-101 as well as multiple similar programs in the fields of cardiovascular, metabolism and renal disease.

Christopher Jeffers, PhD, JD

Interim Chief Executive Officer

Rakesh Dixit, PhD

Rakesh Dixit, PhD

President and Head of R & D, Co-Founder

Michael King

Chief Financial Officer

Sia Anagnostou, MS, MBA

Head, Corporate Development

Senior Advisory Board

Advisory Board members formerly associated with AZ/MedImmune and have prior experience with REG-101.

Bahija Jallal, PhD

Bahija Jallal, PhD

Chief Executive Officer and Director of the Board at Immunocore Former President Medimmune, EVP AstraZeneca

John Trainer, MBA

John Trainer, MBA

Chief Financial Officer at NexImmune, Inc. Former VP, Head of Partnering and Strategy at Medimmune/AstraZeneca

Joshua Barer

Co-founder, Regio Biosciences

Boaz Hirshberg, MBA

Boaz Hirshberg, MD, MBA

Co-Founder and Clinical Advisor

Technical & Business Advisors

Marc Bonaca, MD

Marc Bonaca, MD

Executive Director of CPC, Cardiologist & Vascular Medicine Specialist

Judy Hsia, MD

Judy Hsia, MD

Chif science officer at CPC, cardiologist & lipidologist, associate Professor of Medicine at CU

Connie Hess, MD

Connie Hess, MD

Clinician-scientist at CPC, interventional cardiologist, MD from Harvard, trained at Massachusetts General Hospital, cardiology fellowship and Masters degree in Health Science at Duke